|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **List of Authors in the Handbook on P3 in the Pharmaceutical Industry 02-13-25** | | | | | |
|  | **Name** | **Affiliation** | **Topic & stage** | **Contact** | **Stage** |
|  | **Constance E. Bagley**  **Rahul Mehendale,** | *Bagley: Bagley Strategic Advisors LLCand visiting professor of law, CBS Law, Copenhagen Business School.*  *Rahul: Interim CEO at Stealth Startup Co, Harvard Business School, Jersey City* | *Abstract received.*  *Title of 1st submition*  *“*Accelerating Therapeutic Innovation: A Framework for AI-Enabled and Data-Driven Pharmaceutical Public-Private Partnerships” | [Constance@bagleystrategic.com](mailto:Constance@bagleystrategic.com)  [Rahul.mehendale@gmail.com](mailto:Rahul.mehendale@gmail.com)  201-499-7886  <http://linkedin.com/in/rahulmehendale>  Will submit by October 24.  1st copy received 3/2/25 | |
|  | **Veronica Vecchi, Professor of Public Management and Policy** | *Bocconi University, School of Management*  Veronica Vecchi is professor of practice in business government relations at Bocconi University school of management (SDA Bocconi), where she is part of the management board as director of research for Government & Society. She serves also as Director of Masan, a research unit dedicated to healthcare procurement. She is author of numerous publications on public private partnerships, impact investing and procurement, which a specific focus on healthcare. | *Abstract received*  *“Proposed Framework to Understand Public-Private Collaboration in the healthcare Domain in Europe.”* | [*Veronica.vecchi@unibocconi.it*](mailto:Veronica.vecchi@unibocconi.it)  *Yes. 7-15-2024*  *We got the first draft, we sent comments and she revises it on 1/29/24.*  *We got back Vecchi’s revised chapter 2/22/25 and it was sent for review by Joe and Jeff.* | |
|  | ***Dr. Jeffrey Sturchio, Chris Collins***  ***Chris Collins***  ***Dr. Mark P. Lagon*** | *Jeffrey: Chair, Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, Visiting Scholar, Institute for Applied Economics and the Study of Business Enterprise at Johns Hopkins University*  *Chris Collins* Chris Collins leads Friends’ efforts to engage U.S. decision makers on the lifesaving work of the Global Fund and the importance of expanding global health investment. At  Mark P. Lagon is Chief Policy Officer at Friends of the Global Fight Against AIDS, Tuberculosis, and Malaria. He is also Senior Fellow at the Trinity Forum, and Adjunct Professor in the MSc in Foreign Service (MSFS) Program at Georgetown University. Previously in the non-profit world, he served as President of Freedom House | Rethinking partnerships in the pharmaceutical sector: building public goods for global health  *Bios received 9/24/2024* | [J\_Sturchio@msn.com](mailto:J_Sturchio@msn.com)  Twitter: @jeffstruchhio  Mobile: 732-691-1430  Phone 703-765-7929 | |
|  | Stefanie Meredith  134 Chemin du Recredoz 9 Champ Verdon 01220 Divonne les Bains France  +33 450 202140 Mobile  & Whats App +33 6 79 100 763 | *NTD* |  | *stiaephanie@globalhealthconsulting.net* | |
|  | [***Jerome.Kim@ivi.int***](mailto:Jerome.Kim@ivi.int)  [***Anh.Wartel@ivi.int***](mailto:Anh.Wartel@ivi.int)  [***Alberto.Cagigi@ivi.int***](mailto:Alberto.Cagigi@ivi.int) | *Waiting for Matthias WHO response*  *Received 11-18-2024.*  Future Pandemic Preparedness and Urgent Responses  Alberto Cagigi1, T Anh Wartel1, Jerome H Kim2,3 | P3s and PDPs in Infectious Disease Vaccine Development: Lessons from COVID-19 for Future Pandemic Preparedness and Urgent Responses  Alberto Cagigi1, T Anh Wartel1, Jerome H Kim2,3 | [Alberto.Cagigi@ivi.int](mailto:Alberto.Cagigi@ivi.int)  Submitted final version. | |
|  | Isaac Akomea-Frimpong  Roksana Jahana Tumpa  Joshua Ofori Nsiah  Portia Tetteh,  Benjamin Botchway4 | Western Sydney University, Sydney Australia  Central Queensland University, Sydney, Australia  Georgia Institute of Technology, Atlanta, USA  Western Sydney University, Sydney Australia  Kwame Nkrumah University of Science and Technology, Kumasi, Ghana | The role of Public Private Partnerships in circular economy of pharmaceutical industry | Isaac AKOMEA-FRIMPONG  i.akomea-frimpong@westernsydney.edu  90943718@westernsydney.edu.au  We sent Isaac our review on 2/12/25, and he confirmed receipt. We expect his revision. | |
|  | David B. Nash, MD, MBA, Yash Shah, Victoria.McMonagle***,*** | Dr. Raymond C. & Doris N. Grandon Professor of Health Policy  Jefferson College of Population Health  901 Walnut Street, 10th Floor  Philadelphia, PA 19107  Ph: (215) 955-6969 || CELL 215 570-2107  [David.Nash@jefferson.edu](mailto:David.Nash@jefferson.edu)  [Jefferson.edu/PopulationHealth](https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.jefferson.edu%2Funiversity%2Fpopulation-health.html&data=05%7C02%7Csimon.hakim%40temple.edu%7Cb49000f93b554940018608dce22c22ea%7C716e81efb52244738e3110bd02ccf6e5%7C0%7C0%7C638633926428711593%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=A2GL3h3oK4SLf0%2B36nmyg4ECakLVZEePdq1jScui5wY%3D&reserved=0)  [LinkedIn](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fdavid-b-nash-md-mba-98b6155%2F&data=05%7C02%7Csimon.hakim%40temple.edu%7Cb49000f93b554940018608dce22c22ea%7C716e81efb52244738e3110bd02ccf6e5%7C0%7C0%7C638633926428733403%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=nigYtksgWjTgSr1R0g%2Bv%2BcehWWNVNbIuhKdKEuN%2B8Zo%3D&reserved=0) | *Evaluation and policy implications of Jefferson graduate education programs with Pharmaceutical companies.* | [Nash@jefferson.edu](mailto:Nash@jefferson.edu) [yashah01@gmail.com](mailto:yashah01@gmail.com) [Victoria.McMonagle@jefferson.edu](mailto:Victoria.McMonagle@jefferson.edu)  They sent the draft paper. Joe and Simon reviewed it and made comments. Joe got to finalize our suggestions and send it to Jefferson as of 2-2-2025/ | |
|  | Dr. EunBin Chung  Associate professor of Political ScienceScience. | [Eunbin.chung@utah.edu](mailto:Eunbin.chung@utah.edu)  Department of Political Science University of Utah [extension://efaidnbmnnnibpcajpcglclefindmkaj/https://faculty.utah.edu/bytes/curriculumVitae.hml?id=u6002209sci.utah.edu](mailto:eunbin.chung@poli-sci.utah.edu) | *Dedline March 31, 2024.*  *“Learning From Past Pandemic Governance: Early Response and Public-Private Partnerships in Testing of COVID-19 in South Korea,”* | We got an abstract and approved it. He is working on it as of 2-2-25. | |
|  | Associate Professor Hilde StevensStevens | *Universite libre de Bruxelles, Brussels, Belgium. Department of Health Innovations & Society*  *Co-Director, Institute for Interdisciplinary Innovations in Healthcare.* | She holds the Chair in Translational Medicine supported by the Fund Baillet Latour. She focuses her research on patient-centricity, collaborative innovation models, intellectual property (IP) and mechanisms governing access to medicines in the least developed countries (LDCs). | [hstevens@i3health.eu](mailto:hstevens@i3health.eu) | |
| 1. ***7*** | Priya Agrawal | Vice President, Health Equity and Partnerships, MSD International | *Awaiting title and abstract* | [Priya.agrawal@msd.com](mailto:Priya.agrawal@msd.com)  +41 76 336 17 88 | |
|  | Luz Hegemann, Nicola Lister, and Gesa Pellier | Dr. Lutz Hegemann is President, Global Health & Swiss Country Affairs, Novartis International AG  Dr. Nicola Lister is Head, Global Medica Affairs, Global Health, Novartis Pharma AG  Dr. Gesa Pellier is Head, Global Health Programs, Global Health, Novartis Pharma AG | “Partnerships in Global Health – the Novartis Perspective”  *Abstract received* | Key contact:  [Nicola.lister@novartis.com](mailto:Nicola.lister@novartis.com)  +41 79 892 2687  [Lutz.Hegemann@novartis.com](mailto:Lutz.Hegemann@novartis.com)  [Gesa.Pellier@novartis.com](mailto:Gesa.Pellier@novartis.com) | |
|  | Dr. Harald Nusser | Head, Global Health & Health Equity, Merck KGaA | *Awaiting title and abstract* | [Harald.Nusserr@merckgroup.com](mailto:Harald.Nusserr@merckgroup.com)  +49 151 1454 0092 | |
| 1. | Rajni Samavedam | Managing Partner and CEO, Rabin Martin | *Awaiting title and abstract* | [Rajni.Samavedam@rabinmartin.com](mailto:Rajni.Samavedam@rabinmartin.com)  +1 240 308 0132 | |
|  | Niels Lund and Louise Hesseldahl | Senior Partner, Senior Director, Advocacy and Partnerships, Global Health Equity, Novo Nordisk | *Awaiting title and abstract – will focus on the Cities Changing Diabetes Program* | [nlnd@novonordisk.com](mailto:nlnd@novonordisk.com) +45-30797870 (mobile) | |